pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
fda recalls·4d ago·1 min read
save

Ana Salazar Modela Tu Cuerpo recalls Lipofit Extreme Fat Burner 2.0 after FDA finds undeclared fluoxetine and DNP

Aug 27, 2026·read at fda recalls ↗CRLNegative

Ana Salazar Modela Tu Cuerpo Inc. announced a voluntary nationwide recall of its Lipofit Extreme Fat Burner 2.0 on August 27, 2026, targeting the lot with expiration in September 2027.

FDA laboratory analysis detected undeclared fluoxetine in the daytime tablets and undeclared 2,4-dinitrophenol (DNP) in the nighttime tablets.

Fluoxetine is a prescription antidepressant, while DNP is a toxic chemical used industrially and not approved for weight-loss or any dietary supplement use.

Because the product contains these unapproved ingredients, it is considered an unapproved new drug and is being recalled to the consumer level to protect public health.

source

This writeup was produced by pharmadog from original reporting by fda recalls.

Original headline: “Ana Salazar Modela Tu Cuerpo Inc. Issues Nationwide Voluntary Recall of Lipofit Extreme Fat Burner 2.0 Due to Presence of Undeclared Fluoxetine and 2,4-Dinitrophenol (DNP)”

read at fda recalls ↗
614 words · retrieved 11h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RHYTHM
drugs
FLUOXETINE8
topics
Recall6Cardiology3DermatologyEpilepsyMajor DepressionNeurologyObesityOrthopedics

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Jun 4Male puberty is understudied — but when it starts may predict long-term health risksSTAT
  • Dec 22Fierce Biotech Fundraising Tracker '26: AusperBio adds $120M; Abcuro secures $66MFierce Biotech
  • May 12A year after Vertex’s big launch, pain drug research faces a pivotal momentBioPharma Dive
  • 3d agoSTAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT